AstraZeneca (AZN) Q1 2022 Earnings Call Transcript

For the period ending March 31, 2022

April 29, 2022 03:00 a.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Chris Sheldon - Head of Investor Relations

Hello and good afternoon, everybody. I'm Chris Sheldon, head of Investor Relations AstraZeneca I'm pleased to welcome you to AstraZeneca is first quarter 2022 conference call. All materials presented today are available on our web page. Slide two has the usual Safe Harbor statements will be making comments on our performance using constant exchange rates or C Corp financial numbers and other non GAAP measures. And non GAAP to GAAP reconciliation is contained within the results announcements. numbers used are in millions of US dollars. And for the first quarter of 2022 unless stated otherwise, please advance to slide three. This slide shows our agenda for today's call in a moment, I'll hand you over to our CEO Pascal Sario. To begin following our prepared remarks we'll open the line for questions we ask that you limit yourself to one question and one follow up to give everybody a fair opportunity to participate in the q&a during the allotted time. As a reminder for those on the phone, please join in the queue for questions by pressing star one. Please advance to Slide four. And with that Pascal over to you.

Pascal Sariot - CEO

Thank you, Chris. Hello everybody and welcome to this call. We had a strong start of the year reporting first quarter total revenue of about $11.4 billion an increase in six of 60% total revenues when excluding vaccine every year for the quarter who at 50% COVID EPS was $1.89 an increase of 20% over the prior year last quarter, benefiting from phasing in operational expenses which our CFO had now we'll cover in more detail in a moment. Importantly, we deliver bought best performance across our diverse array this is area, oncology gold 25% CVI increased 18% And I increased 4% and rare disease increased 7% on a pro forma basis.

Our new consolidated vaccine and immune therapies ARIA VMI. Deliver a total revenue of $1.8 billion This is the first quarter we've reported sales from this new this area, which includes our COVID-19 vaccine vaccine area and our long acting antibody over shield, as well as synergies and FluMist. And soon hopefully, near 70 Mab each car Hague Executive Vice President of VNA was responsible for leading overnight This is Ari activities is joining us for q&a. We again so Robert news flows news flow in the quarter including you upheaval in lupus, for South Nilo USA poll in j&j foil tumulus and US party reviews for both on how to how to mutant lung cancer and the combination of imfinzi and minimum ARB in advanced liver cancer.